Halozyme Therapeutics, Inc.
HALO
$38.57
$0.110.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 26.75% | 3.38% | 45.07% | 38.25% | 77.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.75% | 3.38% | 45.07% | 38.25% | 77.93% |
| Cost of Revenue | 13.83% | 12.68% | 41.22% | 91.36% | 104.09% |
| Gross Profit | 33.90% | -0.73% | 46.92% | 21.78% | 66.14% |
| SG&A Expenses | 137.29% | 2.33% | -32.24% | 170.04% | 15.06% |
| Depreciation & Amortization | 235.28% | -34.39% | 56.41% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.68% | -0.34% | 6.99% | 160.38% | 87.13% |
| Operating Income | 7.39% | 8.99% | 177.33% | -28.90% | 70.53% |
| Income Before Tax | 42.92% | 38.06% | 210.41% | -29.80% | 29.16% |
| Income Tax Expenses | 20.61% | 65.02% | 151.19% | -11.73% | 209.44% |
| Earnings from Continuing Operations | 47.98% | 32.78% | 229.53% | -34.09% | -13.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.98% | 32.78% | 229.53% | -34.09% | -13.58% |
| EBIT | 7.39% | 8.99% | 177.33% | -28.90% | 70.53% |
| EBITDA | 20.25% | -1.64% | 147.11% | -4.19% | 79.63% |
| EPS Basic | 55.12% | 37.37% | 244.98% | -32.80% | -10.44% |
| Normalized Basic EPS | 16.44% | 23.30% | 215.04% | -30.21% | 77.18% |
| EPS Diluted | 54.62% | 38.64% | 250.00% | -32.56% | -6.93% |
| Normalized Diluted EPS | 17.51% | 23.87% | 220.59% | -29.86% | 77.87% |
| Average Basic Shares Outstanding | -4.61% | -3.34% | -4.50% | -1.91% | -3.52% |
| Average Diluted Shares Outstanding | -5.46% | -3.81% | -6.10% | -2.39% | -3.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
